The NIH starts spending $1.5 billion in new Brain Research through Advancing Innovative Neuro-technologies (BRAIN) projects


NIH Starts to Spend $4.8 Bil­lion in “Extra” Cures Drug Research Mon­ey (P&T Community):

The Nation­al Insti­tutes of Health (NIH) launched 110 new brain research projects in the fis­cal year end­ing last Sep­tem­ber (2017) with the first por­tion of the $1.5 bil­lion over 10 years it will hope­ful­ly receive from the 21st Cen­tu­ry Cures Act, which spread a total of $4.8 bil­lion over four NIH pro­grams. That is mon­ey over and above the NIH annu­al appro­pri­a­tion from Con­gress. The oth­er three “Inno­va­tion Funds” are: Pre­ci­sion Med­i­cine, Can­cer Moon­shot, and Regen­er­a­tive Medicine.

The $1.5 bil­lion in new Brain Research through Advanc­ing Inno­v­a­tive Neu­ro-tech­nolo­gies (BRAIN) research mon­ey seems par­tic­u­lar­ly impor­tant giv­en the announce­ment in Jan­u­ary that Pfiz­er was end­ing its Alzheimer’s research pro­gram after years of fruit­less devel­op­ment efforts, which have plagued oth­er com­pa­nies as well…A prime exam­ple is the “All of Us” ini­tia­tive, which is the pri­ma­ry focus of the Pre­ci­sion Med­i­cine Ini­tia­tive (PMI). While the FDA is using Cures mon­ey to aggre­gate patient post-mar­ket­ing data, the NIH will be col­lect­ing patient data in order to learn about med­ical con­di­tions and to assem­ble a crit­i­cal mass of poten­tial clin­i­cal tri­al par­tic­i­pants. The NIH is part­ner­ing with five com­pa­nies to cre­ate a par­tic­i­pant tech­nol­o­gy center.

Get­ting all these part­ners on board would have been near­ly impos­si­ble had not the Cures Act includ­ed some­thing called Oth­er Trans­ac­tions Author­i­ty for PMI, mak­ing it pos­si­ble for NIH to move for­ward with unprece­dent­ed speed and flex­i­bil­i­ty to car­ry out beta test­ing of all the many com­po­nents, and now a planned launch in the spring of 2018,” NIH Direc­tor Fran­cis Collins, MD, PhD, told the House Ener­gy and Com­merce Com­mit­tee on Novem­ber 30, 2017. “It will also be a plat­form where many clin­i­cal tri­als can also get start­ed because these par­tic­i­pants will have been pre-con­sent­ed for con­tact to see if they would be inter­est­ed in tak­ing part in a clin­i­cal tri­al, say, for dia­betes or Alzheimer’s risks.”

News in Context

About SharpBrains

SHARPBRAINS is an independent think-tank and consulting firm providing services at the frontier of applied neuroscience, health, leadership and innovation.
SHARPBRAINS es un think-tank y consultoría independiente proporcionando servicios para la neurociencia aplicada, salud, liderazgo e innovación.

Top Articles on Brain Health and Neuroplasticity

Top 10 Brain Teasers and Illusions


Subscribe to our e-newsletter

* indicates required

Got the book?